Российские пациенты начали получать новый радиофармпрепарат для борьбы с раком на основе актиния-225
Шесть человек, проходящих лечение в Федеральном научно-клиническом центре медицинской радиологии и онкологии в Димитровграде, стали первыми пользователями радиофармпрепарата актиния-225-ПСМА местного производства. Этот препарат предназначен для терапии неоперабельных метастатических форм рака и был разработан при сотрудничестве с Научно-исследовательским институтом атомных реакторов, который входит в состав госкорпорации «Росатом».
Актиний-225, производимый в ГНЦ НИИАР, представляет собой альфа-эмиттер, который высокоэффективен в адресной терапии онкологических заболеваний.
Ученые отмечают, что терапия актинием-225 особенно эффективна для лечения кастрационно-резистентного рака предстательной железы, который трудно поддается традиционным методам.
Новый радиофармпрепарат способствует обеспечению доступности жизненно важного лечения для российских больниц и уменьшает зависимость от зарубежных поставок.
В избранное
Чтобы оставлять комментарии, нужно войти или зарегистрироваться.
Комментарии (19)
Can you be more specific about the content of your article? After reading it, I still have some doubts. Hope you can help me.
Thank you, your article surprised me, there is such an excellent point of view. Thank you for sharing, I learned a lot. http://5842150.cryptostarthome.com
Can you be more specific about the content of your article? After reading it, I still have some doubts. Hope you can help me.
Thank you for your sharing. I am worried that I lack creative ideas. It is your article that makes me full of hope. Thank you. But, I have a question, can you help me?
Thank you, your article surprised me, there is such an excellent point of view. Thank you for sharing, I learned a lot.
Your point of view caught my eye and was very interesting. Thanks. I have a question for you.
Thanks for sharing. I read many of your blog posts, cool, your blog is very good.
Can you be more specific about the content of your article? After reading it, I still have some doubts. Hope you can help me.
Your point of view caught my eye and was very interesting. Thanks. I have a question for you.
Thank you for your sharing. I am worried that I lack creative ideas. It is your article that makes me full of hope. Thank you. But, I have a question, can you help me?
Thank you for your sharing. I am worried that I lack creative ideas. It is your article that makes me full of hope. Thank you. But, I have a question, can you help me?
Your article helped me a lot, is there any more related content? Thanks! https://www.binance.com/cs/join?ref=S5H7X3LP
Fantastic read! 👏 I really appreciate how clearly you explained the topic—your writing not only shows expertise but also makes the subject approachable for a wide audience. It’s rare to come across content that feels both insightful and practical at the same time. At explodingbrands.de we run a growing directory site in Germany that features businesses from many different categories. That’s why I truly value articles like yours, because they highlight how knowledge and visibility can create stronger connections between people, services, and opportunities.Keep up the great work—I’ll definitely be checking back for more of your insights! 🚀
Your article helped me a lot, is there any more related content? Thanks!
I don’t think the title of your article matches the content lol. Just kidding, mainly because I had some doubts after reading the article.
I don’t think the title of your article matches the content lol. Just kidding, mainly because I had some doubts after reading the article.
Can you be more specific about the content of your article? After reading it, I still have some doubts. Hope you can help me. binance
I don’t think the title of your article matches the content lol. Just kidding, mainly because I had some doubts after reading the article.
Can you be more specific about the content of your article? After reading it, I still have some doubts. Hope you can help me.